A critical review of the relationship between post-transplant atherosclerotic events and cytomegalovirus exposure in kidney transplant recipients

References

• Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601–2614.
   PubMed Web of Science ®Google Scholar
• Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, et al. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991;72(Pt 9):2059–2064.
   PubMed Web of Science ®Google Scholar
• Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91:119–126.
   PubMed Web of Science ®Google Scholar
• Khaiboullina SF, Maciejewski JP, Crapnell K, et al. Human cytomegalovirus persists in myeloid progenitors and is passed to the myeloid progeny in a latent form. Br J Haematol. 2004;126:410–417.
   PubMed Web of Science ®Google Scholar
• Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation. 2006;82:S15–17.
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz M, Arias M, Campistol JM, et al. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice. Transpl Int. 2015;28:1042–1054.
   PubMed Web of Science ®Google Scholar
• Torre-Cisneros J, Aguado JM, Castón JJ, et al. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev (Orlando). 2016;30:119–143.
   PubMedGoogle Scholar
• Sarmiento E, Jaramillo M, Calahorra L, et al. Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: A multicenter prospective study. J Heart Lung Transplant. 2017;36:529–539.
   PubMed Web of Science ®Google Scholar
• Tan L, Sato N, Shiraki A, et al. Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection. Antiviral Res. 2019;162:30–38.
   PubMed Web of Science ®Google Scholar
• Malvezzi P, Jouve T, Rostaing L. Use of everolimus-based immunosuppression to decrease cytomegalovirus infection after kidney transplant. Exp Clin Transplant. 2016;14:361–366.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients: guidelines of the American Society of transplantation infectious diseases community of practice. Clin Transplant. 2019;e13512. DOI:10.1111/ctr.13512
   PubMedGoogle Scholar
• Tedesco-Silva H, Pascual J, Viklicky O, et al. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM Study. Transplantation. 2019;103:1953–1963.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91.
   PubMed Web of Science ®Google Scholar
• Frascaroli G, Varani S, Blankenhorn N, et al. Human cytomegalovirus paralyzes macrophage motility through down-regulation of chemokine receptors, reorganization of the cytoskeleton, and release of macrophage migration inhibitory factor. J Immunol. 2009;182:477–488.
   PubMed Web of Science ®Google Scholar
• Terrazzini N, Bajwa M, Vita S, et al. A novel cytomegalovirus-induced regulatory-type T-cell subset increases in size during older life and links virus-specific immunity to vascular pathology. J Infect Dis. 2014;209:1382–1392.
   PubMed Web of Science ®Google Scholar
• Cederarv M, Soderberg-Naucler C, Odeberg J. HCMV infection of PDCs deviates the NK cell response into cytokine-producing cells unable to perform cytotoxicity. Immunobiology. 2009;214:331–341.
   PubMed Web of Science ®Google Scholar
• L’Huillier AG, Ferreira VH, Ku T, et al. Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients. Am J Transplant. 2019;19:2495–2504.
   PubMedGoogle Scholar
• Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8:975–983.
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Slifkin M, Ruthazer R, et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis. 2004;39:1293–1299.
   PubMed Web of Science ®Google Scholar
• Florescu DF, Mindru C, Chambers HE, et al. Clostridium difficile and cytomegalovirus colitis co-infection: search for the hidden ‘bug’. Transpl Infect Dis. 2011;13:411–415.
   PubMed Web of Science ®Google Scholar
• Matas AJ, Gillingham KJ, Humar A, et al. 2202 kidney transplant recipients with 10 years of graft function: what happens next? Am J Transplant. 2008;8:2410–2419.
   PubMed Web of Science ®Google Scholar
• de Mattos AM, Prather J, Olyaei AJ, et al. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int. 2006;70:757–764.
   PubMed Web of Science ®Google Scholar
• Ki EL L, Venetz JP, Meylan P, et al. Cytomegalovirus infection and new-onset post-transplant diabetes mellitus. Clin Transplant. 2008;22:245–249.
   PubMed Web of Science ®Google Scholar
• Soule JL, Streblow DN, Andoh TF, et al. Cytomegalovirus accelerates chronic allograft nephropathy in a rat renal transplant model with associated provocative chemokine profiles. Transplant Proc. 2006;38:3214–3220.
   PubMed Web of Science ®Google Scholar
• Waters S, Lee S, Affandi JS, et al. The effect of genetic variants affecting NK cell function on cardiovascular health and the burden of CMV. Hum Immunol. 2017;78:747–751.
   PubMed Web of Science ®Google Scholar
• van de Berg PJ, Yong SL, Remmerswaal EB, et al. Cytomegalovirus-induced effector T cells cause endothelial cell damage. Clin Vaccine Immunol. 2012;19:772–779.
   PubMedGoogle Scholar
• Sacre K, Hunt PW, Hsue PY, et al. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS. 2012;26:805–814.
   PubMed Web of Science ®Google Scholar
• Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006;20:2275–2283.
   PubMed Web of Science ®Google Scholar
• Roberts ET, Haan MN, Dowd JB, et al. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol. 2010;172:363–371.
   PubMed Web of Science ®Google Scholar
• Li M, Boddeda SR, Chen B, et al. NK cell and Th17 responses are differentially induced in murine cytomegalovirus infected renal allografts and vary according to recipient virus dose and strain. Am J Transplant. 2018;18:2647–2662.
   PubMed Web of Science ®Google Scholar
• Elwenspoek MMC, Sias K, Hengesch X, et al. T cell immunosenescence after early life adversity: association with cytomegalovirus infection. Front Immunol. 2017;8:1263.
   PubMed Web of Science ®Google Scholar
• Yu HT, Park S, Shin EC, et al. T cell senescence and cardiovascular diseases. Clin Exp Med. 2016;16:257–263.
   PubMed Web of Science ®Google Scholar
• Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28− and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011;134:17–32.
   PubMed Web of Science ®Google Scholar
• Cantisan S, Torre-Cisneros J, Lara R, et al. Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation. Clin Vaccine Immunol. 2009;16:1429–1438.
   PubMedGoogle Scholar
• Pachnio A, Ciaurriz M, Begum J, et al. Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-specific CD4+ T cells targeted to vascular endothelium. PLoS Pathog. 2016;12:e1005832.
   PubMed Web of Science ®Google Scholar
• DuRose JB, Li J, Chien S, et al. Infection of vascular endothelial cells with human cytomegalovirus under fluid shear stress reveals preferential entry and spread of virus in flow conditions simulating atheroprone regions of the artery. J Virol. 2012;86:13745–13755.
   PubMed Web of Science ®Google Scholar
• Bentz GL, Yurochko AD. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins. Proc Natl Acad Sci USA. 2008;105:5531–5536.
   PubMed Web of Science ®Google Scholar
• Gredmark-Russ S, Dzabic M, Rahbar A, et al. Active cytomegalovirus infection in aortic smooth muscle cells from patients with abdominal aortic aneurysm. J Mol Med (Berl). 2009;87:347–356.
   PubMed Web of Science ®Google Scholar
• Gredmark S, Jonasson L, Van Gosliga D, et al. Active cytomegalovirus replication in patients with coronary disease. Scand Cardiovasc J. 2007;41:230–234.
   PubMed Web of Science ®Google Scholar
• Sutherland MR, Raynor CM, Leenknegt H, et al. Coagulation initiated on herpesviruses. Proc Natl Acad Sci USA. 1997;94:13510–13514.
   PubMed Web of Science ®Google Scholar
• Persoons MC, Stals FS, van Dam Mieras MC, et al. Multiple organ involvement during experimental cytomegalovirus infection is associated with disseminated vascular pathology. J Pathol. 1998;184:103–109.
   PubMed Web of Science ®Google Scholar
• Bruggeman CA, Debie WH, Muller AD, et al. Cytomegalovirus alters the von Willebrand factor content in human endothelial cells. Thromb Haemost. 1988;59:264–268.
   PubMedGoogle Scholar
• Goeijenbier M, van Wissen M, van de Weg C, et al. Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol. 2012;84:1680–1696.
   PubMed Web of Science ®Google Scholar
• Assinger A, Kral JB, Yaiw KC, et al. Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses. Arterioscler Thromb Vasc Biol. 2014;34:801–809.
   PubMed Web of Science ®Google Scholar
• Popovic M, Smiljanic K, Dobutovic B, et al. Human cytomegalovirus infection and atherothrombosis. J Thromb Thrombolysis. 2012;33:160–172.
   PubMed Web of Science ®Google Scholar
• Gerna G, Baldanti F, Revello MG. Pathogenesis of human cytomegalovirus infection and cellular targets. Hum Immunol. 2004;65:381–386.
   PubMed Web of Science ®Google Scholar
• Li L, Li Y, Dai Z, et al. Lipid metabolism in vascular smooth muscle cells infuenced by HCMV infection. Cell Physiol Biochem. 2016;39:1804–1812.
   PubMedGoogle Scholar
• Sanchez V, Dong JJ. Alteration of lipid metabolism in cells infected with human cytomegalovirus. Virology. 2010;404:71–77.
   PubMed Web of Science ®Google Scholar
• Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res. 2006;71:247–258.
   PubMed Web of Science ®Google Scholar
• Dhaunsi GS, Kaur J, Turner RB. Role of NADPH oxidase in cytomegalovirus-induced proliferation of human coronary artery smooth muscle cells. J Biomed Sci. 2003;10:505–509.
   PubMed Web of Science ®Google Scholar
• Simanek AM, Dowd JB, Pawelec G, et al. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011;6:e16103.
   PubMed Web of Science ®Google Scholar
• Adam E, Melnick JL, Probtsfield JL, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet. 1987;2:291–293.
   PubMed Web of Science ®Google Scholar
• Safaie N, Ghotaslou R, Montazer Ghaem H. Seroprevalence of cytomegalovirus in patients with and without coronary artery diseases at Madani Heart Center, Iran. Acta Med Iran. 2010;48:403–406.
   PubMedGoogle Scholar
• Wang H, Peng G, Bai J, et al. Cytomegalovirus infection and relative risk of cardiovascular disease (ischemic heart disease, stroke, and cardiovascular death): a meta-analysis of prospective studies up to 2016. J Am Heart Assoc. 2017;6:7. .
   Web of Science ®Google Scholar
• Smieja M, Gnarpe J, Lonn E, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107:251–257.
   PubMed Web of Science ®Google Scholar
• Heybar H, Alavi SM, Farashahi Nejad M, et al. Cytomegalovirus infection and atherosclerosis in candidate of coronary artery bypass graft. Jundishapur J Microbiol. 2015;8:e15476.
   PubMed Web of Science ®Google Scholar
• Beyaz MO, Ugurlucan M, Oztas DM, et al. Evaluation of the relationship between plaque formation leading to symptomatic carotid artery stenosis and cytomegalovirus by investigating the virus DNA. Arch Med Sci Atheroscler Dis. 2019;4:e19–e24.
   PubMedGoogle Scholar
• Nerheim PL, Meier JL, Vasef MA, et al. Enhanced cytomegalovirus infection in atherosclerotic human blood vessels. Am J Pathol. 2004;164:589–600.
   PubMed Web of Science ®Google Scholar
• Izadi M, Fazel M, Saadat SH, et al. Cytomegalovirus localization in atherosclerotic plaques is associated with acute coronary syndromes: report of 105 patients. Methodist Debakey Cardiovasc J. 2012;8:42–46.
   PubMedGoogle Scholar
• Nikitskaya EA, Grivel JC, Maryukhnich EV, et al. Cytomegalovirus in plasma of acute coronary syndrome patients. Acta Naturae. 2016;8:102–107.
   PubMed Web of Science ®Google Scholar
• Wikby A, Johansson B, Olsson J, et al. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002;37:445–453.
   PubMed Web of Science ®Google Scholar
• Neppelenbroek SIM, Rootjes PA, Boxhoorn L, et al. Cytomegalovirus-associated thrombosis. Neth J Med. 2018;76:251–254.
   PubMed Web of Science ®Google Scholar
• Ceccarelli M, Venanzi Rullo E, Nunnari G. Risk factors of venous thrombo-embolism during cytomegalovirus infection in immunocompetent individuals. A systematic review. Eur J Clin Microbiol Infect Dis. 2018;37:381–390.
   PubMed Web of Science ®Google Scholar
• Tumilowicz JJ, Gawlik ME, Powell BB, et al. Replication of cytomegalovirus in human arterial smooth muscle cells. J Virol. 1985;56:839–845.
   PubMed Web of Science ®Google Scholar
• Hernandez D, Hanson E, Kasiske MK, et al. Cytomegalovirus disease is not a major risk factor for ischemic heart disease after renal transplantation. Transplantation. 2001;72:1395–1399.
   PubMed Web of Science ®Google Scholar
• Komorowska-Jagielska K, Heleniak Z, Debska-Slizien A. Cytomegalovirus status of kidney transplant recipients and cardiovascular risk. Transplant Proc. 2018;50:1868–1873.
   PubMedGoogle Scholar
• Pouria S, State OI, Wong W, et al. CMV infection is associated with transplant renal artery stenosis. QJM. 1998;91:185–189.
   PubMedGoogle Scholar
• Humar A, Gillingham K, Payne WD, et al. Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation. 2000;70:310–313.
   PubMed Web of Science ®Google Scholar
• Kalil RS, Hudson SL, Gaston RS. Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus? Am J Transplant. 2003;3:79–81.
   PubMed Web of Science ®Google Scholar
• Gomez E, Laures A, Baltar JM, et al. Cytomegalovirus replication and “herpesvirus burden” as risk factor of cardiovascular events in the first year after renal transplantation. Transplant Proc. 2005;37:3760–3763.
   PubMed Web of Science ®Google Scholar
• Ozdemir FN, Akgul A, Altunoglu A, et al. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. Transplant Proc. 2007;39:990–992.
   PubMed Web of Science ®Google Scholar
• Courivaud C, Bamoulid J, Chalopin JM, et al. Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients. J Infect Dis. 2013;207:1569–1575.
   PubMed Web of Science ®Google Scholar
• Price P, Lee S, Affandi J, et al. Cytomegalovirus antibody and vascular pathology in renal transplant recipients. J Med Virol. 2017;89:177–181.
   PubMed Web of Science ®Google Scholar
• San-Juan R, De Dios B, Garcia-Reyne A, et al. Limited impact of cytomegalovirus infection in the long-term outcome of renal and liver transplant. J Clin Virol. 2013;56:316–322.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 2013;26:703–727.
   PubMed Web of Science ®Google Scholar
• Lee S, Brook E, Affandi J, et al. A high burden of cytomegalovirus marks poor vascular health in transplant recipients more clearly than in the general population. Clin Transl Immunology. 2019;8:e1043.
   PubMed Web of Science ®Google Scholar
• Rezaee-Zavareh MS, Ajudani R, Khosravi MH, et al. Effect of cytomegalovirus exposure on the atherosclerotic events among kidney-transplanted patients: a systematic review and meta-analysis. Nephro Urology Mon. 2018;10. doi:10.5812/numonthly.63900.
   Google Scholar
• Toz H, Duman S, Altunel E, et al. Intima media thickness as a predictor of atherosclerosis in renal transplantation. Transplant Proc. 2004;36:156–158.
   PubMed Web of Science ®Google Scholar
• Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol. 2005;16:496–506.
   PubMed Web of Science ®Google Scholar
• Manuel O, Perrottet N, Pascual M. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. Expert Rev Anti Infect Ther. 2011;9:955–965.
   PubMed Web of Science ®Google Scholar
• Reischig T, Hribova P, Jindra P, et al. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2012;23:1588–1597.
   PubMed Web of Science ®Google Scholar
• Reischig T, Kacer M, Hes O, et al. Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. Am J Transplant. 2019;19:2457–2467.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143:870–880.
   PubMed Web of Science ®Google Scholar
• Merola J, Jane-Wit DD, Pober JS. Recent advances in allograft vasculopathy. Curr Opin Organ Transplant. 2017;22:1–7.
   PubMed Web of Science ®Google Scholar
• Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation. 1999;100:61–66.
   PubMed Web of Science ®Google Scholar
• Spinner ML, Saab G, Casabar E, et al. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation. 2010;90:412–418.
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B. Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients. Transplantation. 2015;99:1197–1202.
   PubMed Web of Science ®Google Scholar
• Serrano-Alonso M, Guillen-Grima F, Martin-Moreno P, et al. Reduction in mortality associated with secondary cytomegalovirus prophylaxis after solid organ transplantation. Transpl Infect Dis. 2018;20:e12873.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015;162:1–10.
   PubMed Web of Science ®Google Scholar
• Traynor C, Jenkinson A, Williams Y, et al. Twenty-year survivors of kidney transplantation. Am J Transplant. 2012;12:3289–3295.
   PubMed Web of Science ®Google Scholar
• Morales JM, Marcen R, Del Castillo D, et al. Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrol Dial Transplant. 2012;27(Suppl 4):iv39–46.
   PubMedGoogle Scholar
• Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation. 2006;114:1608–1615.
   PubMed Web of Science ®Google Scholar
• San-Juan R, Navarro D, Garcia-Reyne A, et al. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients. Transpl Infect Dis. 2015;17:637–646.
   PubMed Web of Science ®Google Scholar
• Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int. 2005;67:2454–2461.
   PubMed Web of Science ®Google Scholar